Trial record 1 of 1 for:    NCT01155479
Previous Study | Return to List | Next Study

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (P05664 AM5)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01155479
First received: June 30, 2010
Last updated: August 30, 2013
Last verified: August 2013
  Purpose

This is a one year, 2-part study to determine the efficacy and safety of preladenant, an adenosine type 2a (A2a)receptor antagonist. The purpose of Part 1 (first 26 weeks) is to determine if preladenant is effective in the treatment of early Parkinson's Disease. The purpose of Part 2 (second 26 weeks) is to determine if preladenant is safe and well tolerated.


Condition Intervention Phase
Parkinson Disease
Drug: Preladenant 2 mg tablet
Drug: Preladenant 5 mg tablet
Drug: Preladenant 10 mg tablet
Drug: Rasagiline 1 mg capsule
Drug: Placebo for Rasagiline 1 mg capsule
Drug: Placebo for Preladenant
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's Disease (Phase 3 Protocol No. P05664)

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Change from Baseline in the Sum of Unified Parkinson's Disease Rating Scale Parts 2 and 3 scores (UPDRS2+3) [ Time Frame: Baseline and Week 26 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of Responders (Participants with a ≥20% improvement in UPDRS2+3) [ Time Frame: Baseline and Week 26 ] [ Designated as safety issue: No ]
  • Change from Baseline in the UPDRS Part 2 score (Activities of Daily Living [ADL]) [ Time Frame: Baseline and Week 26 ] [ Designated as safety issue: No ]

Enrollment: 1022
Study Start Date: July 2010
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Preladenant 2 mg
2 mg Preladenant Tablet + Placebo for Rasagiline in AM; 2 mg Preladenant in PM
Drug: Preladenant 2 mg tablet
one 2 mg tablet orally twice daily
Other Name: SCH 420814
Drug: Placebo for Rasagiline 1 mg capsule
one capsule orally in AM
Experimental: Preladenant 5 mg
5 mg Preladenant Tablet + Placebo for Rasagiline in AM; 5 mg Preladenant in PM
Drug: Preladenant 5 mg tablet
one 5 mg tablet orally twice daily
Other Name: SCH 420814
Drug: Placebo for Rasagiline 1 mg capsule
one capsule orally in AM
Experimental: Preladenant 10 mg
10 mg Preladenant Tablet + Placebo for Rasagiline in AM; 10 mg Preladenant in PM
Drug: Preladenant 10 mg tablet
one 10 mg tablet orally twice daily
Other Name: SCH 420814
Drug: Placebo for Rasagiline 1 mg capsule
one capsule orally in AM
Placebo Comparator: Placebo
Placebo for preladenant + Placebo Rasagiline in AM; Placebo for preladenant in PM
Drug: Placebo for Preladenant
one tablet orally twice daily
Active Comparator: Rasagiline
1 mg Rasagiline Capsule + Placebo for preladenant in AM; Placebo for preladenant in PM
Drug: Rasagiline 1 mg capsule
one 1 mg capsule orally in AM
Other Name: Azilect

  Eligibility

Ages Eligible for Study:   30 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has a diagnosis of idiopathic PD for < 5 years
  • If receiving amantadine and/or anticholinergics must have been on a stable regimen of treatment for at least the 5 weeks immediately before Screening. (Note: Subjects who are not taking any medications for PD are permitted to enroll in this trial.)
  • Must have a UPDRS Part 3 score of ≥10, a Hoehn and Yahr Stage ≥3, be ≥30 to ≤85

years of age, and have results of Screening clinical laboratory tests drawn within 3 weeks prior to

Randomization, clinically acceptable to the investigator, and not within the parameters specified for exclusion

- If sexually active or plan to be sexually active, must agree to use a highly effective method of birth control while the subject is in the study and for 2 weeks after the last dose of study drug. A male subject must also not donate sperm during the trial and within 2 weeks after the

last dose of study drug

Exclusion Criteria:

  • Must not have a form of drug induced or atypical Parkinsonism, cognitive impairment (ie, Montreal Cognitive Assessment [MoCA] score <22), bipolar disorder, untreated major depressive disorder, schizophrenia, or other psychotic disorder; history of exposure to a known neurotoxin, or any neurological features not consistent with the diagnosis of PD as assessed by the investigator
  • Must not have had surgery for PD
  • Must not have a history of repeated strokes with stepwise progression of Parkinsonism or head injuries, or a stroke within 6 months of

Screening; poorly controlled diabetes; abnormal renal function; or a severe or ongoing unstable medical condition

  • Must not have failed to show a therapeutic response if a diagnostic levodopa (L dopa) challenge had been done with a large test dose (>500 mg) of L dopa (if malabsorption excluded), or failed to respond to an adequate previous treatment with dopaminergic therapy.
  • Must not have been treated with L dopa or dopamine agonists for 30 days or more. A participant who has been treated with L-dopa or dopamine agonists for <30 days will be allowed to enter the study. These participants must stop taking dopaminergic medication 30 days prior to Randomization.
  • Must not be at imminent risk of self-harm or harm to others
  • Must not have elevated blood pressure (BP) (systolic BP ≥150 mm Hg or diastolic BP ≥95 mm Hg) that cannot be adequately controlled with antihypertensive medication, as demonstrated by 2 BP measurements meeting acceptable BP criterion at consecutive scheduled or unscheduled visits between Screening and Randomization (a 5-6 week period), one of which must be the Randomization visit.
  • Must not have had any clinically significant cardiovascular event or procedure for 6 months prior to Randomization, including, but not limited to, myocardial infarction, angioplasty, unstable angina, or heart failure; and a subject must not have heart failure staged New York Heart Association Class III or IV
  • Must not have an alanine aminotransferase (ALT) or aspartate amino transferase (AST) > 3 x the upper limit of normal (ULN) or total bilirubin (T BIL) > 1.5 x ULN
  • Must not have active serologically-confirmed hepatic dysfunction (defined as viral infection [Hepatitis B, C, or E; Epstein-Barr virus (EBV)]; cytomegalovirus [CMV] or a history of diagnosis of drug- or alcohol-induced hepatic toxicity or frank hepatitis, or a history of diagnosis of drug- or alcohol-induced hepatic toxicity or frank hepatitis
  • Must not have a history within the past 5 years of a primary or recurrent malignant disease with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or in situ prostate cancer with a normal prostate-specific antigen (PSA) post resection
  • Must not have received certain prespecified medications or ingested high tyramine-containing aged cheeses (eg, Stilton) for a prespecified time window before the trial, during the trial, and for 2 weeks after the trial.
  • Must not have an average daily consumption of more than three 4 ounce glasses (118 mL) of wine or the equivalent.
  • Must not have a severe or ongoing unstable medical condition (eg, any form of clinically significant cardiac disease, symptomatic orthostatic hypotension, seizures, or alcohol/drug dependence).
  • Must not have allergy/sensitivity to investigational product(s) or its/their excipients.
  • Must not be breast-feeding, considering breast-feeding, pregnant or intending to become

pregnant.

- Must not have used preladenant ever, or any investigational drugs within 90 days immediately before Screening.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Additional Information:
No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01155479     History of Changes
Other Study ID Numbers: P05664, 2009-013552-72
Study First Received: June 30, 2010
Last Updated: August 30, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Rasagiline
Monoamine Oxidase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 28, 2014